Vineti, a provider of a digital platform of record for personalized therapies, and WuXi AppTec Advanced Therapies, a CDMO, have entered into a collaborative agreement to combine Vineti’s ordering and traceability platform with WuXi’s manufacturing facilities in an effort to bring an end-to-end solution to mutual customers.
 
The collaboration aims to leverage platforms from both WuXi Advanced Therapies and Vineti so that more novel therapies are able to be developed, manufactured, tested and released faster and with greater predictability, compliance and patient safety to benefit patients worldwide.
 
“We are excited to establish a collaboration with WuXi AppTec Advanced Therapies to enable developers of innovative and personalized advanced therapies manufacturing at WuXi AppTec’s Advanced Therapies facilities to enjoy the benefits of our Personalized Therapy Management Platform (PTM), providing logistics, scheduling, distribution, tracking, Chain of Identity, Chain of Custody, and Chain of Condition in real time,” said Amy DuRoss, chief executive officer and co-founder of Vineti.
 
“We are pleased to be part of Vineti’s partnership program to support both customers that seek to promote streamlining personalized therapies from specimen connections to manufacturing,” said Felix Hsu, senior vice president and global head of WuXi AppTec Advanced Therapies. “With our leading integrated manufacturing and testing services, we believe we can bring even more speed, reliability and security to an already complex manufacturing and supply chain. We are committed to helping our partners deliver more innovative therapies to patients and the market sooner.”